Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET (original) (raw)

• SEER: The Surveillance, Epidemiology, and End Results Program: Cancer of the Prostate Statistics 2008. http://seer.cancer.gov/statfacts/html/prost.html.
• Frank, I. N., Graham Jr, S. & Nabors, W. L. Urologic and Male Genital Cancers. In American Cancer Society Textbook of Clinical Oncology (Eds Holleb, A. I., Fink, D. J. & Murphy, G. P.) 280–283 (New York, American Cancer Society, 1991).
  Google Scholar
• Kessler, B. & Albertsen, P. The natural history of prostate cancer. Urol. Clin. North Am. 30, 219–226 (2003).
  Article PubMed Google Scholar
• Small, E. J. Prostate cancer: incidence, management and outcomes. Drugs Aging 13, 71–81 (1998).
  Article CAS PubMed Google Scholar
• Ploch, N. R. & Brawer, M. K. How to use prostate-specific antigen. Urology 43 (2 Suppl.), 27–35 (1994).
  Article CAS PubMed Google Scholar
• Lukes, M. et al. Prostate-specific antigen: current status. Folio Biol. (Praha) 47, 41–49 (2001).
  CAS Google Scholar
• Boccon-Gibod, L. Prostate-specific antigen or PSA. Facts and probabilities [French]. Presse Med. 24, 1471–1472 (1995).
  CAS PubMed Google Scholar
• Safa, A. A. et al. Undetectable serum prostate-specific antigen associated with metastatic prostate cancer: a case report and review of the literature. Am. J. Clin. Oncol. 21, 323–326 (1998).
  Article CAS PubMed Google Scholar
• Sella, A. et al. Low PSA metastatic androgen-independent prostate cancer. Eur. Urol. 38, 250–254 (2000).
  Article CAS PubMed Google Scholar
• Beardo, P. et al. Undetectable prostate specific antigen in disseminated prostate cancer. J. Urol. 166, 993 (2001).
  Article CAS PubMed Google Scholar
• Lofters, A. et al. “PSA-itis”: knowledge of serum prostate specific antigen and other causes of anxiety in men with metastatic prostate cancer. J. Urol. 168, 2516–2520 (2002).
  Article PubMed Google Scholar
• Dong, J. T. et al. Prostate cancer—biology of metastasis and its clinical implications. World J. Urol. 14, 182–189 (1996).
  Article CAS PubMed Google Scholar
• Yu, K. K. & Hricak, H. Imaging prostate cancer. Radiol. Clin. North Am. 38, 59–85 (2000).
  Article PubMed Google Scholar
• Yu, K. K. & Hawkins, R. A. The prostate: diagnostic evaluation of metastatic disease. Radiol. Clin. North Am. 38, 139–157 (2000).
  Article CAS PubMed Google Scholar
• Dotan, Z. A. Bone imaging in prostate cancer. Nat. Clin. Pract. Urol. 5, 434–444 (2008).
  Article PubMed Google Scholar
• Fair, W. R., Israeli, R. S. & Heston, W. D. Prostate-specific membrane antigen. Prostate 32, 140–148 (1997).
  Article CAS PubMed Google Scholar
• Haseman, M. K., Rosenthal, S. A. & Polascik, T. J. Capromab pendetide imaging of prostate cancer. Cancer Biother. Radiopharm. 15, 131–140 (2000).
  Article CAS PubMed Google Scholar
• Harisinghani, M. G. et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 348, 2491–2499 (2003).
  Article PubMed Google Scholar
• Phelps, M. E. PET: the merging of biology and imaging into molecular imaging. J. Nucl. Med. 41, 661–681 (2000).
  CAS PubMed Google Scholar
• Gambhir, S. S. Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer 2, 683–693 (2002).
  Article CAS PubMed Google Scholar
• Basu, S. & Alavi, A. Unparalleled contribution of 18F-FDG PET to medicine over 3 decades. J. Nucl. Med. 49, 17N–21N, 37N (2008).
  Article PubMed Google Scholar
• National Oncologic PET Registry. http://www.cancerPETregistry.org.
• Hillner, B. E. et al. Impact of positron emission tomography/computed tomography and positron mission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J. Clin. Oncol. 26, 4229 (2008).
  Article Google Scholar
• Hillner, B. E. et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the National Oncologic PET Registry. J. Nucl. Med. 49, 1928–1935 (2008).
  Article PubMed Google Scholar
• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
  Article CAS PubMed Google Scholar
• Gambhir, S. S. Molecular imaging of cancer: from molecules to humans. Introduction. J. Nucl. Med. 49 (Suppl. 2), 1S–4S (2008).
  Article PubMed Google Scholar
• Haberkorn, U. et al. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl. Med. Biol. 21, 827–834 (1994).
  Article CAS PubMed Google Scholar
• Clavo, A. C., Brown, R. S. & Wahl, R. L. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J. Nucl. Med. 36, 1625–1632 (1995).
  CAS PubMed Google Scholar
• Pauwels, E. K. et al. FDG accumulation and tumor biology. Nucl. Med. Biol. 25, 317–322 (1998).
  Article CAS PubMed Google Scholar
• Mochizuki, T. et al. FDG uptake and glucose transporter subtype expression in experimental tumor and inflammation models. J. Nucl. Med. 42, 1551–1555 (2001).
  CAS PubMed Google Scholar
• Gillies, R. J., Robey, I. & Gatenby, R. A. Causes and consequences of increased glucose metabolism of cancers. J. Nucl. Med. 49 (6 Suppl.), 24S–42S (2008).
  Article CAS PubMed Google Scholar
• Plathow, C. & Weber, W. A. Tumor cell metabolism imaging. J. Nucl. Med. 49 (6 Suppl.), 43S–63S (2008).
  Article CAS PubMed Google Scholar
• Gatenby, R. A. & Gillies, R. J. A microenvironmental model of carcinogenesis. Nat. Rev. Cancer 8, 56–61 (2008).
  Article CAS PubMed Google Scholar
• uman Genome Organisation (HUGO) Gene Nomenclature Committee. http://www.genenames.org.
• Macheda, M. L., Rogers, S. & Bets, J. D. Molecular and cellular regulation of glucose transport (GLUT) proteins in cancer. J. Cell Physiol. 202, 654–662 (2005).
  Article CAS PubMed Google Scholar
• Mathupala, S. P., Ko, Y. H. & Pederson, P. L. Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25, 4777–4786 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Smith, T. A. Mammalian hexokinases and their abnormal expression in cancer. Br. J. Biomed. Sci. 57, 170–178 (2000).
  CAS PubMed Google Scholar
• Caraco, C. et al. Cellular release of [18F]2-fluoro-2-deoxyglucose as a function of the glucose-6-phosphatates enzyme system. J. Biol. Chem. 275, 18489–18494 (2000).
  Article CAS PubMed Google Scholar
• Effert, P. et al. Expression of glucose transporter 1 (GLUT-1) in cell lines and clinical specimen from human prostate adenocarcinoma. Anticancer Res. 24, 3057–3063 (2004).
  CAS PubMed Google Scholar
• Chandler, J. D. et al. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer 97, 2035–2042 (2003).
  Article CAS PubMed Google Scholar
• Stewardt, G. D. et al. Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter 1 expression correlate with Gleason score. Oncol. Rep. 20, 1561–1567 (2008).
  Google Scholar
• Hara, T., Bansal, A. & DeGrado, T. R. Effect of hypoxia on the uptake of [methyl-3H]choline, [1–14C]acetate and [18F]FDG in cultured prostate cancer cells. Nucl. Med. Biol. 33, 977–984 (2006).
  Article CAS PubMed Google Scholar
• Palayoor, S. T., Tofilon, P. J. & Coleman, C. N. Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1α and HIF-2α in prostate cancer cells. Clin. Cancer Res. 9, 3150–3157 (2003).
  CAS PubMed Google Scholar
• Jadvar, H. et al. Glucose metabolism of human prostate cancer mouse xenografts. Mol. Imaging 4, 91–97 (2005).
  Article PubMed Google Scholar
• Oyama, N. et al. MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model. Nucl. Med. Biol. 29, 783–790 (2002).
  Article CAS PubMed Google Scholar
• Agus, D. B. et al. Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res. 58, 3009–3014 (1998).
  CAS PubMed Google Scholar
• Apolo, A. B., Pandit-Taskar, N. & Morris, M. J. Novel tracers and their development for the imaging of metastatic prostate cancer. J. Nucl. Med. 49, 2031–2041 (2008).
  Article PubMed Google Scholar
• Takahashi, N. et al. The roles of PET and PET/CT in the diagnosis and management of prostate cancer. Oncology 72, 226–233 (2007).
  Article PubMed Google Scholar
• Salminen, E. et al. Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol. 41, 425–429 (2002).
  Article PubMed Google Scholar
• Pugachev, A. et al. Dependence of FDG uptake on tumor microenvironment. Int. J. Radiat. Oncol. Biol. Phys. 62, 545–553 (2005).
  Article CAS PubMed Google Scholar
• Etchebehere, E. C. et al. Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of 18F-FDG PET. Q. J. Nucl. Med. 46, 122–130 (2002).
  CAS PubMed Google Scholar
• Turlakow, A. et al. local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose: comparison of filtered back projection and iterative reconstruction with segmented attenuation correction. Q. J. Nucl. Med. 45, 235–244 (2001).
  CAS PubMed Google Scholar
• Vandenberghe, S. et al. Iterative reconstruction algorithms in nuclear medicine. Comput. Med. Imaging Graph. 25, 105–111 (2001).
  Article CAS PubMed Google Scholar
• Jadvar, H. et al. [F-8]-fluorodeoxyglucose PET–CT of the normal prostate gland. Ann. Nucl. Med. 22, 787–793 (2008).
  Article PubMed PubMed Central Google Scholar
• Effert, P. J. et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J. Urol. 155, 994–998 (1996).
  Article CAS PubMed Google Scholar
• Hofer, C. et al. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur. Urol. 36, 31–35 (1999).
  Article CAS PubMed Google Scholar
• Patel, P. et al. Evaluation of metabolic activity of prostate gland with PET–CT. J. Nucl. Med. 43 (5 Suppl.), 119P (2002).
  Google Scholar
• von Mallek, D. et al. Technical limits of PET/CT with 18FDG in prostate cancer [German]. Aktuelle Urol. 37, 218–221 (2006).
  Article CAS PubMed Google Scholar
• Liu, I. J. et al. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57, 108–111 (2001).
  Article CAS PubMed Google Scholar
• Kao, P. F., Chou, Y. H. & Lai, C. W. Diffuse FDG uptake in acute prostatitis. Clin. Nucl. Med. 33, 308–310 (2008).
  Article PubMed Google Scholar
• Oyama, N. et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J. Clin. Oncol. 29, 623–629 (1999).
  Article CAS PubMed Google Scholar
• Kanamaru, H. et al. Evaluation of prostate cancer using FDG-PET [Japanese]. Hinyokika Kiyo 46, 851–853 (2000).
  CAS PubMed Google Scholar
• Lucignani, G., Paganelli, G. & Bombardieri, E. The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective. Nucl. Med. Commun. 25, 651–656 (2004).
  Article CAS PubMed Google Scholar
• Shreve, P. D. et al. Metastatic prostate cancer: initial findings of PET with FDG. Radiology 199, 751–756 (1996).
  Article CAS PubMed Google Scholar
• Morris, N. J. et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 59, 913–918 (2002).
  Article PubMed Google Scholar
• Yeh, S. D. et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl. Med. Biol. 23, 693–697 (1996).
  Article CAS PubMed Google Scholar
• Jadvar, H., Pinski, J. & Conti, P. FDG PET in suspected recurrent and metastatic prostate cancer. Oncol. Rep. 10, 1485–1488 (2003).
  PubMed Google Scholar
• Jadvar, H. et al. Concordance among FDG PET, CT and bone scan in men with metastatic prostate cancer. Presented at the 55th Annual Meeting of the Society of Nuclear Medicine, 2008 June 15–19, New Orleans, LA.
• Chang, C. H. et al. Detecting metastatic pelvic lymph nodes by (18)F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol. Int. 70, 311–315 (2003).
  Article PubMed Google Scholar
• Schoder, H. et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin. Cancer Res. 11, 4761–4769 (2005).
  Article PubMed Google Scholar
• Sanz, G. et al. Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int. 84, 1028–1031 (1999).
  Article CAS PubMed Google Scholar
• Sung, J. et al. Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer. BJU Int. 92, 24–27 (2003).
  Article CAS PubMed Google Scholar
• Seltzer, M. A. et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J. Urol. 162, 1322–1328 (1999).
  Article CAS PubMed Google Scholar
• Oyama, N. et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl. Med. Commun. 22, 963–969 (2001).
  Article CAS PubMed Google Scholar
• Zhang, Y. et al. Longitudinally quantitative 2-deoxy-2-[18F]fluoro-D-glucose micro positron emission tomography imaging for efficacy of new anticancer drugs: a case study with bortezomib in prostate cancer murine model. Mol. Imaging Biol. 8, 300–308 (2006).
  Article CAS PubMed Google Scholar
• Haberkorn, U. et al. PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine. J. Nucl. Med. 38, 1215–1221 (1997).
  CAS PubMed Google Scholar
• Morris, M. J. et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin. Cancer Res. 11, 3210–3216 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Oyama, N. et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol. Imaging Biol. 4, 99–104 (2002).
  Article PubMed Google Scholar
• Farsad, M. et al. Positron-emission tomography in imaging and staging prostate cancer. Cancer Biomark. 4, 277–284 (2008).
  Article CAS PubMed Google Scholar
• Dimitrakopoulou-Strauss, A. & Strauss, L. G. PET imaging of prostate cancer with 11C-acetate. J. Nucl. Med. 44, 556–558 (2003).
  PubMed Google Scholar
• Reske, S. N. et al. Imaging prostate cancer with 11C-choline PET/CT. J. Nucl. Med. 47, 1249–1254 (2006).
  CAS PubMed Google Scholar
• Nunez, R. et al. Combined 18F-FDG and C-11 methionine PET scans in patients with newly progressive metastatic prostate cancer. J. Nucl. Med. 43, 46–55 (2002).
  PubMed Google Scholar
• Larson, S. M. et al. Tumor localization of 16β-18F-fluoro-5α-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J. Nucl. Med. 45, 366–373 (2004).
  CAS PubMed Google Scholar
• Schuster, D. M. et al. Initial experience with radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J. Nucl. Med. 48, 56–63 (2007).
  CAS PubMed Google Scholar
• Mease, R. C. et al. N-[N-[(S)-1, 3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-l-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin. Cancer Res. 14, 3036–3043 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Even-Sapir, E. et al. The detection of bone metastases in patients with high risk prostate cancer:99mTc-MDP planar bone scintigraphy, single- and multi-filed-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J. Nucl. Med. 47, 287–297 (2006).
  PubMed Google Scholar